Eskalith

Drug Overview

Eskalith is a foundational medication within Psychiatry, representing one of the oldest and most effective treatments for severe mood instability. It belongs to the Mood Stabilizer Drug Class and utilizes lithium as its active ingredient. Despite the development of newer psychiatric drugs over the last several decades, lithium formulations like Eskalith remain the “gold standard” for managing Bipolar Disorder, particularly for their unparalleled ability to prevent manic relapses and reduce suicide risk.

• Generic Name / Active Ingredient: Lithium carbonate
• US Brand Names: Eskalith (Historically available as immediate-release capsules; extended-release forms like Eskalith CR have also been utilized, though generic lithium carbonate is most common today).
• Route of Administration: Oral (Capsules, Tablets)
• FDA Approval Status: Fully FDA-Approved

What Is It and How Does It Work? (Mechanism of Action)

Unlike most psychiatric drugs that bind to specific receptors (like keyholes) on the outside of brain cells, lithium is a simple elemental ion (similar to sodium) that enters the neuron and alters its internal machinery.

While its exact mechanism is still being mapped, Eskalith works primarily by inhibiting two critical enzymes inside the brain cell:

1. Inositol Monophosphatase (IMPase): Overactive signaling in the brain (which causes mania) relies on a chemical recycling system called the phosphoinositide cycle. Lithium blocks IMPase, which slows down this recycling process. This effectively puts a “speed limit” on how fast neurons can fire, dampening the runaway electrical activity that causes manic episodes.
2. Glycogen Synthase Kinase-3 beta (GSK-3 \beta ): Lithium strongly inhibits this enzyme. In doing so, it promotes neuroplasticity—the brain’s ability to grow, adapt, and repair itself. Over time, inhibiting GSK-3 \beta  increases levels of a protective protein called BDNF (Brain-Derived Neurotrophic Factor), which helps repair the cellular damage caused by chronic manic and depressive episodes.

By slowing down overactive circuits and simultaneously repairing damaged cells, Eskalith provides a profound stabilizing effect on mood.

FDA-Approved Clinical Indications

Primary Psychiatric Indications

• Bipolar Disorder: Approved for the acute treatment of manic episodes and for long-term maintenance therapy to prevent or diminish the intensity of subsequent manic and depressive episodes.

Off-Label / Neurological Indications

Because of its powerful stabilizing and neuroprotective properties, psychiatrists frequently utilize lithium off-label for:

• Treatment-Resistant Depression (TRD): Used as an augmenting agent alongside standard antidepressants; it is highly effective at boosting mood in patients who have not responded to multiple therapies.
• Suicide Prevention: Lithium is one of the only psychiatric medications proven to independently and significantly reduce the risk of completed suicide in patients with mood disorders.
• Cluster Headaches: Occasionally used for the prophylaxis (prevention) of chronic cluster headaches when standard neurological treatments fail.

Dosage and Administration Protocols

Dosing Eskalith is highly individualized and relies entirely on strict blood monitoring. Lithium has a very narrow therapeutic index, meaning the difference between an effective dose and a toxic dose is very small.

Special Population Adjustments:

• Renal (Kidney) Insufficiency: Lithium is cleared 100% by the kidneys. Patients with mild to moderate kidney disease require significantly lower doses and intense monitoring. It is generally contraindicated in severe renal failure.
• Elderly Patients: Older adults clear lithium much slower and are highly sensitive to toxicity (causing severe confusion and tremors). Target blood levels are typically kept very low (e.g., 0.4 to 0.6 mEq/L).

Clinical Efficacy and Research Results

Current psychiatric guidelines (2020-2026) unequivocally maintain lithium as a first-line treatment for Bipolar Disorder, highlighting its unique long-term benefits.

• Manic Episode Efficacy: In acute mania, lithium demonstrates response rates (a >50% reduction in Young Mania Rating Scale scores) of 60% to 70%, matching or exceeding newer atypical antipsychotics, though it can take 7 to 10 days to achieve full effect.
• Relapse Prevention: Long-term clinical data shows that continuous lithium therapy reduces the risk of a manic relapse by over 50% compared to placebo. It is significantly more effective at preventing new manic episodes than preventing depressive ones.
• Anti-Suicidal Properties: Meta-analyses from 2020-2026 confirm that lithium reduces the rate of suicide attempts and completed suicides by nearly 80% in patients with Bipolar Disorder, a protective effect not consistently seen with anticonvulsant mood stabilizers (like valproate or carbamazepine).

Safety Profile and Side Effects

BLACK BOX WARNING: LITHIUM TOXICITY

Lithium toxicity is closely related to serum lithium levels and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy. Mild toxicity can cause hand tremors, diarrhea, and vomiting; severe toxicity can lead to seizures, coma, permanent brain damage, or death.

Common Side Effects (>10%)

• Fine hand tremor (often treated with a beta-blocker if bothersome)
• Increased thirst (polydipsia) and frequent urination (polyuria)
• Nausea or mild gastrointestinal upset
• Weight gain
• Hypothyroidism (lithium interferes with thyroid hormone production)

Serious Adverse Events

• Lithium Toxicity: As detailed in the Black Box Warning.
• Renal Toxicity: Long-term use (decades) can occasionally cause chronic kidney disease or nephrogenic diabetes insipidus (the kidneys lose the ability to concentrate urine).
• Cardiac Arrhythmias: Can occasionally disrupt the heart’s electrical rhythm, causing a condition called sick sinus syndrome.
• Ebstein’s Anomaly: If taken during the first trimester of pregnancy, lithium slightly increases the risk of a rare, specific heart defect in the developing fetus.

Management Strategies

• For Toxicity: If a patient develops a sudden, severe tremor, mental confusion, vomiting, or slurred speech, they must go to the emergency room immediately. Severe toxicity is treated with aggressive IV fluids or, in extreme cases, hemodialysis to physically filter the drug out of the blood.
• For Thyroid Issues: Up to 20% of patients develop an underactive thyroid. This is easily managed by prescribing a daily thyroid hormone supplement (levothyroxine) while continuing the lithium.

Research Areas

Current neurological research (2020-2026) is heavily focused on lithium’s remarkable neuroprotective properties. Because lithium strongly inhibits the GSK-3 \beta  enzyme, it actively stimulates the production of stem cells and neurotrophic factors in the brain’s hippocampus. Researchers are conducting clinical trials to see if low-dose lithium can be used as a Targeted Therapy to slow or halt the progression of neurodegenerative diseases, specifically Alzheimer’s Disease and Amyotrophic Lateral Sclerosis (ALS), by physically repairing damaged neural pathways and preventing the buildup of toxic tau proteins in the brain.

Disclaimer: This information is a research hypothesis, not established clinical facts. It may be biologically plausible, but it is not yet validated for routine medical practice or regenerative-medicine use in humans.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Renal Panel: Baseline BUN and Creatinine to ensure healthy kidneys.
• Thyroid Panel: Baseline TSH to ensure healthy thyroid function.
• Electrocardiogram (ECG): Recommended for patients over 40 or with a history of heart disease.
• Pregnancy Test: Mandatory for women of childbearing age due to the risk of fetal heart defects.

Precautions During Treatment:

• Blood Level Monitoring: Blood must be drawn regularly (e.g., every 3-6 months once stable) to check lithium levels, kidney function, and thyroid function. Blood must be drawn exactly 12 hours after the last dose to be accurate.
• Hydration and Sodium: Lithium acts like salt in the body. If a patient becomes dehydrated (from sweating, diarrhea, or hot weather), the kidneys hold onto lithium, causing rapid, dangerous toxicity. Patients must maintain a consistent salt and water intake.

Do’s and Don’ts:

• DO drink plenty of water (8-12 glasses daily) and maintain a normal salt diet.
• DO take the medication with meals to reduce stomach upset.
• DON’T take over-the-counter NSAIDs (like Ibuprofen, Advil, or Aleve). These painkillers restrict blood flow to the kidneys, causing lithium levels to spike dangerously. Use acetaminophen (Tylenol) instead.
• DON’T start any new blood pressure medications (especially ACE inhibitors or diuretics/water pills) without telling your doctor, as they severely interact with lithium.
• DON’T stop the medication abruptly. This triggers a massive rebound of severe mania and greatly increases the risk of suicide.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Due to the strict blood monitoring required, lithium therapy must be heavily supervised by a licensed medical professional. Always seek the advice of your physician regarding any medical condition, treatment options, or drug interactions. Do not disregard professional medical advice or delay seeking it based on the contents of this drug profile.